Heike Heckroth
Bayer Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Heike Heckroth.
Neuropharmacology | 2008
F. Josef van der Staay; Kris Rutten; Lars Bärfacker; Jean DeVry; Christina Erb; Heike Heckroth; Dagmar Karthaus; Adrian Tersteegen; Marja van Dr. Kampen; Arjan Blokland; Jos Prickaerts; Klaus G. Reymann; Ulrich H. Schröder; Martin Hendrix
The present study investigated the putative pro-cognitive effects of the novel selective PDE9 inhibitor BAY 73-6691. The effects on basal synaptic transmission and long-term potentiation (LTP) were investigated in rat hippocampal slices. Pro-cognitive effects were assessed in a series of learning and memory tasks using rodents as subjects. BAY 73-6691 had no effect on basal synaptic transmission in hippocampal slices prepared from young adult (7- to 8-week-old) Wistar rats. A dose of 10 microM, but not 30 microM, BAY 73-6691 enhanced early LTP after weak tetanic stimulation. The dose effective in young adult Wistar rats did not affect LTP in hippocampal slices prepared from young (7- to 8-week-old) Fischer 344 X Brown Norway (FBNF1) rats, probably reflecting strain differences. However, it increased basal synaptic transmission and enhanced early LTP after weak tetanic stimulation in hippocampal slices prepared from very old (31- to 35-month-old) FBNF1 rats. BAY 73-6691 enhanced acquisition, consolidation, and retention of long-term memory (LTM) in a social recognition task and tended to enhance LTM in an object recognition task. Bay 73-6691 attenuated the scoplamine-induced retention deficit in a passive avoidance task, and the MK-801-induced short-term memory deficits in a T-maze alternation task. The mechanism of action, possibly through modulation of the NO/cGMP-PKG/CREB pathway, is discussed. Our findings support the notion that PDE9 inhibition may be a novel target for treating memory deficits that are associated with aging and neurodegenerative disorders such as Alzheimers disease.
Archive | 2003
Hilmar Bischoff; Elke Dittrich-Wengenroth; Martina Wuttke; Heike Heckroth; Wolfgang Thielemann; Michael Woltering; Michael Otteneder
Archive | 2004
Samir Bennabi; Heike Heckroth; Hartmut Schirok; Joachim Mittendorf; Raimund Kast; Johannes-Peter Stasch; Mark Jean Gnoth; Klaus Münter; Dieter Lang; Santiago Figueroa Perez; Marcus Bauser; Achim Feurer; Heimo Ehmke
Archive | 2003
Michael Woltering; Hilmar Bischoff; Elke Dittrich-Wengenroth; Heike Heckroth; Michael Otteneder
Archive | 2003
Achim Feurer; Samir Bennabi; Heike Heckroth; Jens Ergüden; Thomas Schenke; Markus Bauser; Raimund Kast; Johannes-Peter Stasch; Elke Stahl; Klaus Münter; Dieter Lang; Heimo Ehmke
Archive | 2012
Lars Baerfacker; Heike Heckroth; Martin Hendrix; Dagmar Karthaus; Adrian Tersteegen; アドリアン・テルシュテーゲン; ダグマール・カルトハウス; ハイケ・ヘックロート; マルティン・ヘンドリクス; ラルス・ベルファッカー
Archive | 2007
Jens-Kerim Ergüden; Perez Santiago Figueroa; Ingo Flamme; Heike Gielen-Haertwig; Rolf Grosser; Heike Heckroth; Peter Kolkhof; Alexander Kuhl; Dieter Dr. Lang; Karl-Heinz Schlemmer
Archive | 2007
Eva-Maria Becker; Jens-Kerim Ergüden; Perez Santiago Figueroa; Ingo Flamme; Heike Gielen-Haertwig; Rolf Grosser; Heike Heckroth; Peter Kolkhof; Alexander Kuhl; Karl-Heinz Schlemmer
Archive | 2007
Alexander Kuhl; Peter Kolkhof; Heike Heckroth; Karl-Heinz Schlemmer; Ingo Flamme; Santiago Figueroa Perez; Heike Gielen-Haertwig; Jens-Kerim Ergüden
Archive | 2007
Alexander Kuhl; Peter Kolkhof; Heike Heckroth; Karl-Heinz Schlemmer; Ingo Flamme; Santiago Figueroa Perez; Heike Gielen-Haertwig; Jens-Kerim Ergüden